首页>投融资
Asceneuron
C轮
Asceneuron, a biotech company, is spun-out from Merck Serono in October 2012 as part of the company's Entrepreneur Partnership Program. Asceneuron is focused on the development of Alzheimer's disease and related neurological diseases such as tauopathies.In September 2015, the company raised CHF 30 million (US $30.6 million) in a series A financing roundIn October 2012, Merck Serono was to invest EUR 5 million (US $6.43 million) as seed funding; by May 2013, the investment had been completed
基本信息
-
公司全称Asceneuron SA
-
类型神经退行性疾病疗法开发商
-
产业领域药品研发/制造
-
公司人数15人以下
-
地址EPFL Innovation Park Batiment B LAUSANNE VAUD 1015; CH;
-
联系电话+41 21 693 8245
-
邮箱info@asceneuron.com
-
成立时间2012-01-01
投融资
-
2024-07-16C轮1亿美元诺和诺德LSP Dementia Fund奥博资本SR OneM VenturesSofinnova PartnersGSK Equities InvestmentsJohnson & Johnson Innovation
-
2022-05-04捐赠/众筹未透露Michael J. Fox Foundation
-
2022-05-04捐赠/众筹/授予未透露Michael J. Fox Foundation
-
2021-03-12捐赠/众筹/授予220万美元Alzheimer's Drug Discovery Foundation
-
2016-10-06捐赠/众筹/授予未透露Michael J. Fox Foundation
-
2015-09-29A轮3000万瑞士法郎Sofinnova PartnersJohnson & Johnson InnovationKurma PartnersSR OneM Ventures
- 加载更多
相关投融资企业
收并购
Ipsen SA formerly the Beaufour-Ipsen Group, is a European pharmaceutical group founded in 1929. The group's research and development is targeted to the disease areas of endocrinology, oncology and neuromuscular disorders.In April 2011, Ipsen SA was nearing to completing a strategic review and planned to announce details in June of that year. In June 2011, the company announced restructuring plans in which it would restructure its business into four market-based franchises and focus its R&D on its peptide and tocin-based technologies. The company also planned to merge its R&D departments and close its Barcelona, Spain R&D center.The company planned to create four franchises: Endocrinology/Somatuline (lanreotide depot); Neurology/Dysport (abobotulinumtoxinA); Uro-oncology/Decapeptyl (triptorelin pamoate); and Hemophilia. It also planned to maximize the value of its short stature business, and this was to be managed directly by regions and countries. Ipsen also intended to to grow its primary care
战略投资
丹望医疗科技上海有限公司位于上海南翔精准医学产业园，致力于将最新的再生医学类器官技术临床转化，应用于疾病的诊疗、新药筛选、肿瘤标志物开发与鉴定，努力为临床提供个性化治疗的新技术，为新药研发提供精准、高效、优质的类器官模型。公司拥有全球领先的类器官技术创新平台，已建立了肺、胰腺、乳腺、胃、肠、肝等多个人体器官组织的类器官培养体系。
A轮
Ottimo Pharma是一家私营生物技术公司，由Medicxi和Jonny Finlay于2020年共同创立，专注于开发用于实体瘤的开创性创新癌症疗法。该公司的主导项目Jankistomig是一种PD1-VEGFR2双功能抗体，旨在通过单一IgG疗法同时靶向免疫检查点抑制和血管生成。通过推进这种双途径方法，Ottimo Pharma旨在改善癌症治疗结果，降低总体医疗负担。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息